CD19-CD22-Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy for Pediatric Patients With Acute Lymphoblastic Leukemia

This study is testing a new type of cell therapy called CAR T cell therapy in children and young adults with acute lymphoblastic leukemia (ALL) that has come back or did not respond to previous treatments. The therapy uses the patient's own immune cells, which are genetically engineered to attack leukemia cells that carry specific proteins (CD19 and CD22). **You may be eligible if...** - You are under 21 years old - You have relapsed or refractory ALL that is positive for CD19 and/or CD22 markers - Your leukemia has come back at least twice, came back after a bone marrow transplant, or has not responded to treatment designed to cause remission - Your expected survival is more than 12 weeks - Your performance level (ability to function day-to-day) is adequate **You may NOT be eligible if...** - You have a known primary immune deficiency disorder - You have HIV - You are pregnant or breastfeeding - You have active, uncontrolled infection Talk to your doctor to see if this trial is right for you.